Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Noven Pharmaceuticals

Noven Pharmaceuticals
1987 FOUNDED
M&A STATUS
501-600 EMPLOYEES
M&A LATEST DEAL TYPE
2 FINANCING ROUNDS
4 INVESTMENTS
Description

Manufacturer of pharmaceutical products. The company is engaged in the research, development, manufacturing, licensing, marketing and sale of prescription pharmaceutical products.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Parent Company
Primary Office
  • 11960 South West
  • 144th Street
  • Miami, FL 33186
  • United States

+1 (305) 000-0000

Noven Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Noven Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Noven Pharmaceuticals Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 00000000000000 15-Aug-2007 000000000000000000 00000 Pharmaceuticals
0000000 00000000 0 20-Mar-2007 00000 00000 00 0000 Surgical Devices 000000 0000000
0000000 00000000 0 31-Jan-2003 00000 00000 00 0000 Surgical Devices 000000 0000000
Salient Surgical Technologies 15-Jan-2002 Later Stage VC 000.00 Surgical Devices 000000 0000000
To view this company’s complete investment and acquisition history, request access »

Noven Pharmaceuticals Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 00000000 0 20-Mar-2007 00000 00000 00 0000 Completed
  • 10 buyers
0000000 00000000 0 31-Jan-2003 00000 00000 00 0000 Completed
  • 9 buyers
Salient Surgical Technologies 15-Jan-2002 Later Stage VC 000.00 Completed
  • 14 buyers
To view this company’s complete exits history, request access »

Noven Pharmaceuticals Executive Team (3)

Name Title Board
Seat
Contact
Info
Michael Greene General Counsel & Executive Director

2 Former Executives

You’re viewing 1 of 3 executives. Get the full list »